Thanks John, Appreciate the contributions. In some ways the...

Thanks John,

Appreciate the contributions. In some ways the investment thesis is dependent on developing the end uses...this will substantially de risk the project and may be the catalyst the market is looking for.

My thinking is that demand will be elastic, if prices rise then there is a much likelier shift to cheaper alternatives. Going too vertical might take focus away from core business.

May be wiser to partner with ultra-premium retail brands for perfumes etc (eg LVMH etc) where there is a substantial brand premium which can absorb the higher cost inputs. Obviously clinical trials if successful are great but expensive and add a layer of risk.

I am on the side here as I don't have a good idea of risk/reward currently and not really the sustaining capex but certainly you guys do have a reasonable thesis that may very well play out. I will try to scour the annual reports from awhile ago to answer my questions as a few posters I respect here.